Stock fact sheet · data as of
Journey Medical Corporation (DERM): fair value, margin of safety and Wheel Score
Ticker symbol DERM · Healthcare · Drug Manufacturers - Specialty & Generic · United States · Speculative
Is DERM undervalued?
Journey Medical Corporation (DERM) closed at 4.73 on 5 Nov 2026. None of the nine GLS valuation models produced a positive value for the stock - the company lost money over the last twelve months, EPS -0.22 and it pays no dividend - so there is no GLS average fair value and no margin of safety to report. The quality, option and event numbers below still apply; the Quote page's Wall Street View shows what analysts expect instead.
The nightly engine files DERM under Speculative - it is losing money or its Piotroski health score is 3 or lower - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for DERM
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 0.1465 | -97% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 11.75 | +148% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: DERM passes 4 of the nine Piotroski tests. Our scans drop the stock at the health filter; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 2.7 out of 10: returns on capital, margins or the balance sheet have not shown a lasting edge yet - often a young company, a thin-margin business or one that has only recently turned profitable.
Returns on capital are thin or negative - ROIC -20.0%, ROE -35.9%, ROA -12.1% - with debt at 0.80 times equity and negative free cash flow.
Journey Medical Corporation pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Qbrexza 60%, Accutane 40% (quarter Q2 FY2026).
Institutional ownership scores 5/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 4 / 9 | ROIC | -20.0% |
|---|---|---|---|
| GLS Moat | 2.7 / 10 | ROE | -35.9% |
| Debt / equity | 0.80 | ROA | -12.1% |
| Free-cash-flow yield | -5.6% | Payout ratio | 0% |
| Institutions | 5 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 23: Weak
DERM scores 23 out of 100 on the Wheel Score, in the Weak band (under 50): it fails filter 1, options that actually trade - options too quiet (21 open interest, 3 a day); and filter 2, a real business, not a gamble - speculative (a loss, or a weak Piotroski score); and filter 3, below fair value - trades right at our fair value; and filter 4, financially healthy - Piotroski 4/9 (under 6); and filter 5, can repay its debt - debt with no positive cash flow to repay it; and filter 8, big enough - market cap $134M (under $1.0B); and filter 9, not a penny stock - price 4.73 (under $5), and the parts are thin too - value weak, premium good, moat weak, health fair, red flags fair, option trading weak, stability fair. The score is not a judgement on the company; it says the price, quality and premium do not line up for selling puts on it today.
Implied volatility is 77% on the near-the-money contracts 20-60 days out - above the 60% top of the sweet spot. It still passes the 25-80% filter, but the Wheel Score rewards it less because volatility this high usually comes with a reason. Chain open interest is thin - 21 contracts across every expiry - so fills at a fair price are not guaranteed; a 30-45-day put may not exist at a usable strike.
Volume runs at 118k shares a day on a market cap of $134M, with a beta of 1.15; the Stability part of the Wheel Score rates that fair.
| Filter | Wheel Trade Filter | Result | Detail |
|---|---|---|---|
| 1 | Options that actually trade | Fails | options too quiet (21 open interest, 3 a day) |
| 2 | A real business, not a gamble | Fails | speculative (a loss, or a weak Piotroski score) |
| 3 | Below fair value | Fails | trades right at our fair value |
| 4 | Financially healthy | Fails | Piotroski 4/9 (under 6) |
| 5 | Can repay its debt | Fails | debt with no positive cash flow to repay it |
| 6 | No serious red flags | Passes | Red Flags score 60 or more out of 100 (earnings, margins, debt, analysts, filings and price checked the same way for every stock) |
| 7 | A premium worth selling | Passes | Implied volatility 25-80% (enough premium, not a lottery ticket) |
| 8 | Big enough | Fails | market cap $134M (under $1.0B) |
| 9 | Not a penny stock | Fails | price 4.73 (under $5) |
| How it ranks | Rating | From | |
|---|---|---|---|
| Value | Weak | 0% below fair value | |
| Premium | Good | implied volatility 77% | |
| Moat | Weak | moat 2.7/10 | |
| Health | Fair | Piotroski 4/9 | |
| Red Flags | Fair | Red Flags score 70/100 | |
| Option trading | Weak | 3 contracts a day, 21 open interest | |
| Stability | Fair | beta 1.15, $134M company |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls: a stock must pass all 9 Wheel Trade Filters to score 70, and the score then ranks the ones that pass; the Sunday Scan is the top 10. It is updated nightly and is not a recommendation. How the Wheel Score works · the walkthrough lesson shows how it fits into a trade, start to finish.
Upcoming events
Journey Medical Corporation reports earnings on 11 Nov 2026 (after the close) - inside the 14-day window the Sunday Scan avoids, because a put sold now would carry the report's gap risk.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to Journey Medical Corporation by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| OGI Organigram Global Inc. | 0.9650 | 11.09 | +91% | 30Weak | $136M |
| CRDL Cardiol Therapeutics Inc. | 1.01 | 0.1498 | -574% | 10Weak | $122M |
| BGM BGM Group Ltd. | 9.12 | 6.82 | -34% | 12No options | $116M |
| ORGO Organogenesis Holdings Inc. | 0.8700 | 4.46 | +80% | 21Weak | $112M |
| AAWH Ascend Wellness Holdings, Inc. | 0.3950 | 4.21 | +91% | 25No options | $80M |
| SIGA SIGA Technologies, Inc. | 3.15 | 8.74 | +64% | 35Weak | $226M |
| GLAS Glass House Brands Inc | 2.58 | 54.75 | +95% | 30Weak | $227M |
| LFCR Lifecore Biomedical, Inc. | 6.44 | 0.9450 | -581% | 10Weak | $244M |
| ELTP Elite Pharmaceuticals, Inc. | 0.2400 | 6.18 | +96% | 33No options | $259M |
| CPIX Cumberland Pharmaceuticals Inc. | 4.44 | 22.07 | +80% | 26Weak | $67M |
| ZYBT Zhengye Biotechnology Holding Limited | 1.37 | 1.27 | -7% | 13No options | $65M |
| EBS Emergent BioSolutions Inc. | 5.90 | 45.07 | +87% | 36Weak | $303M |
Scan the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the top 10 stocks that pass all 9 Wheel Trade Filters, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about DERM
Is DERM undervalued right now?
The GLS models could not value DERM (the company lost money over the last twelve months, EPS -0.22 and it pays no dividend), so there is no fair value or margin of safety to compare the price of 4.73 against.
What is the Wheel Score of DERM and what does it mean?
DERM scores 23 out of 100 (Weak) - it fails Wheel Trade Filters 1, 2, 3, 4, 5, 8, 9. The Wheel Score ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned - in two parts: the 9 pass/fail Wheel Trade Filters (busy options, a real business, below fair value, Piotroski 6 or more, debt it can repay, a Red Flags score of 60 or more, implied volatility of 25-80%, a $1 billion company, $5 a share) and a ranking of how strongly a stock passes on value, premium, moat, health, red flags, option trading and stability. A stock that fails any filter stays under 70; 70-84 is Good, 85 and above is Prime. The Sunday Scan is the top 10 that pass, sorted by Wheel Score.
What is the GLS fair value for DERM?
None of the nine GLS models produced a positive value for DERM (the company lost money over the last twelve months, EPS -0.22 and it pays no dividend), so there is no GLS fair value tonight.
When does Journey Medical Corporation report earnings next?
The next earnings report is due on 11 Nov 2026 (after the close), 6 days from the data date of 5 Nov 2026. The Calendars page lists every upcoming report with its time of day.
Does DERM have listed options, and how liquid are they?
Yes. The nightly snapshot found 4 listed contracts with 21 open interest across all expiries and implied volatility of 77% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.